Bi/Multispecific Drugs Surge in Oncology: 278 New Candidates Added in 2024/25
核心洞察
The oncology landscape added 278 new bi- and multispecific drugs during 2024/25, alongside more than 8,566 events across 2,120 drug programs.
Over 800 drugs were associated with new events, underscoring the accelerating pace and complexity of bi- and multispecific drug development.
A new analytical tool tracks 481 therapeutic targets, 167 tumor types, 1,481 clinical trials, and 350 deals, with Amgen, Roche/Genentech, and J&J among leading developers.
The bi- and multispecific drug market is transforming oncology through precision targeting, immune activation, and advanced therapeutic engineering. During 2024/25, the oncology landscape added 278 new bi- and multispecific drugs and recorded more than 8,566 events across 2,120 drug programs, according to a newly launched analytical tool from ResearchAndMarkets.com. More than 800 drugs were associated with new events, highlighting the pace, scale, and increasing complexity of this high-growth segment.
The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" analytical tool provides comprehensive, near-real-time competitive, clinical, and business intelligence. Unlike static market reports, the web-based platform includes a full year of online access, continuous data updates, monthly pipeline alerts, new features, and dedicated support.
Pipeline Scale and Competitive Landscape
The platform monitors more than 870 organizations, including 743 corporate entities, 89 academic organizations, 90 startups, 38 cancer centers or hospitals, and 34 major pharmaceutical or biotechnology companies. Its database covers more than 1,400 drugs, spanning over 420 discovery-stage programs, more than 1,130 preclinical programs, over 300 Phase 1 programs, more than 200 Phase 2 programs, 23 Phase 3 programs, and 21 marketed therapies.
Leading drug developers represented in the database include Amgen, Hoffmann-La Roche and Genentech, Johnson & Johnson, Xencor, and Biocytogen (搜索). The most active countries covered include the United States, China, South Korea, the United Kingdom, and Germany.
Targets, Biomarkers, and Clinical Intelligence
The tool tracks 481 therapeutic targets, 167 tumor types, 1,481 clinical trials, and 464 clinical biomarkers. It enables analysis of more than 3,000 biomarkers, including stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic programs from early development through approval. Clinical development programs can be evaluated using detailed trial intelligence covering dosage, resistance mechanisms, adverse events, food effects, phase and status progression, first-in-human studies, tumor stage and grade, and line of therapy.
The platform also maps combination therapy strategies by target, modality, indication, and trial stage. A total of 197 drugs are evaluated in combination therapy programs, while integrated real-world evidence analytics support segmentation by drug modality, co-medication profile, biomarker cluster, and development stage.
Business Development and Investment Activity
The analytical tool records 350 deals during the last five years and more than 1,800 business development and licensing contacts. It also tracks more than 1,100 funding events during the last five years and intelligence on 231 leading investors, along with 17 worldwide academic-commercial opportunity projects.
AI-Enhanced Intelligence Platform
The tool is powered by an award-winning, artificial intelligence-enhanced intelligence platform with more than 25 years of oncology expertise. It supports business development, search and evaluation, competitive intelligence, clinical development, and portfolio strategy. Proprietary early success and failure indicators help users identify emerging clinical leaders and monitor changes across the competitive landscape.
Users can monitor developments presented at leading oncology and hematology conferences, including AACR, ASCO, ESMO, and ASH, and connect with key opinion leaders, scientific experts, oncology-focused investors, and potential funding partners. The platform is designed to support teams throughout the oncology drug development lifecycle, from early research and target assessment to clinical strategy, partnering, investment, and commercialization.